Everspin Sets $100M Revenue Target for FY2029 Amid Expansion Plans

What happened

Everspin management presented a goal of exceeding $100 million in annual revenue by fiscal 2029 during an Oppenheimer conference, outlining plans to expand its MRAM product portfolio, manufacturing footprint, and revenue base. The target implies roughly fourfold growth from the current run-rate of about $60 million annually, based on Q1 2026 revenue of $14.9 million. This ambition rests on existing initiatives already disclosed: the $40 million Amentum defense subcontract, the Microchip foundry collaboration for second sourcing, and higher-density xSPI MRAM qualification. However, the target is long-term and does not address near-term execution risks such as distributor concentration, point-in-time revenue recognition, litigation costs, and capital obligations. The announcement provides a public benchmark but lacks new details on milestone timing or funding requirements.

Implication

Investors should treat the $100M FY2029 target as aspirational rather than a near-term catalyst. The target implies significant revenue acceleration that hinges on successful execution across multiple fronts: defense program milestones converting to recognized revenue, xSPI volume shipments, and Microchip capacity coming online by 2H27. Current fundamentals show Q1 2026 revenue of $14.9 million with 90% through distributors and almost entirely point-in-time recognition, so near-term visibility remains limited. The stock trades at EV/EBITDA of 203 and P/E of 2127, leaving little room for execution slip-ups. Focus remains on Q2/Q3 2026 filings for Amentum contract accounting signals and H2 2026 for xSPI shipment traction; without these, downside risk increases despite the long-term target.

Thesis delta

The new revenue target does not change the core investment thesis, which hinges on near-term conversion of the Amentum defense subcontract into auditable revenue/cash signals and on xSPI higher-density product ramp. The target provides a long-term benchmark but offers no new information on execution timeline, capital needs, or risk reduction. The thesis remains WAIT with a focus on observable quarterly financial indicators rather than multi-year projections.